Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection, a 'conversion therapy' strategy. However, conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed. Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice. Evidence review: Many research centers in China have accumulated significant experience implementing HCC conversion therapy. Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC; however, there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields. In order to summarize and learn from past experience and review current challenges, the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition) was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice. Sixteen consensus statements on the implementation of conversion therapy for HCC were developed. The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Self-citationEASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124 · cited 2×
“In addition, targeted therapy combined with immunotherapy, such as lenvatinib combined with pembrolizumab, bevacizumab combined with atezolizumab, bevacizumab analogs combined with sintilimab, and apatinib combined with camrelizumab (16-18,41), are associated with ORRs of over 20% in the treatment of unresectable live…”
BackgroundSelf-citationUse of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
Jaeschke, R., Guyatt, G. H., Dellinger, P., Schunemann, H., Levy, M. M., Kunz, R., Norris, S., Bion, J., & for the GRADE working group (2008) · BMJ · doi:10.1136/bmj.a744 · Cited by 577 · cited 1×
“For a recommendation to be graded as strong rather than conditional, at least 70% of participants were required to endorse it as strong (1,2).”
BackgroundKudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2019) · Cancers · doi:10.3390/cancers11081084 · Cited by 309 · cited 1×
“In addition, some studies have reported that for multi-nodular tumors (mostly CNLC stage IIb) that exceed the ‘up-toseven criteria’ (the Kinki criteria), treatment with the TKI lenvatinib leads to a median survival of 37 months (36).”
Background
Cited by
Xie, D., Shi, J., Zhou, J., Fan, J., & Gao, Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0402 · Cited by 177
Self-citation
Metadata
- Authors
- Alliance of Liver Cancer Conversion Therapy, C. O. L. C. O. T. C. A.-C. A., Sun, H.-C., Zhou, J., Wang, Z., Liu, X., Xie, Q., Jia, W., Zhao, M., Bi, X., Li, G., Bai, X., Ji, Y., Xu, L., Zhu, X.-D., Bai, D., Chen, Y., Chen, Y., Dai, C., Guo, R., Guo, W., Hao, C., Huang, T., Huang, Z., Li, D., Li, G., Li, T., Li, X., Li, G., Liang, X., Liu, J., Liu, F., Lu, S., Lu, Z., Lv, W., Mao, Y., Shao, G., Shi, Y., Song, T., Tan, G., Tang, Y., Tao, K., Wan, C., Wang, G., Wang, L., Wang, S., Wen, T., Xing, B., Xiang, B., Yan, S., Yang, D., Yin, G., Yin, T., Yin, Z., Yu, Z., Zhang, B., Zhang, J., Zhang, S., Zhang, T., Zhang, Y., Zhang, Y., Zhang, A., Zhao, H., Zhou, L., Zhang, W., Zhu, Z., Qin, S., Shen, F., Cai, X., Teng, G., Cai, J., Chen, M., Li, Q., Liu, L., Wang, W., Liang, T., Dong, J., Chen, X., Wang, X., Zheng, S., & Fan, J.
- Venue
- Hepatobiliary Surgery and Nutrition
- Publisher
- AME Publishing Company
- Published
- 2022-04
- Volume
- 11
- Issue
- 2
- Pages
- 227-252
- ISSN
- 2304-3881 (ISSN-L)
- 2304-389X
- OpenAlex
- W4211183255
- Cited by
- 206
- References
- 7
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). https://app.cochat.ai/papers/10.21037/hbsn-21-328
- The paper
- Alliance of Liver Cancer Conversion Therapy, C. O. L. C. O. T. C. A.-C. A., Sun, H.-C., Zhou, J., Wang, Z., Liu, X., Xie, Q., Jia, W., Zhao, M., Bi, X., Li, G., Bai, X., Ji, Y., Xu, L., Zhu, X.-D., Bai, D., Chen, Y., Chen, Y., Dai, C., Guo, R., . . . Fan, J. (2022). Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surgery and Nutrition. https://doi.org/10.21037/hbsn-21-328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.